By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ACS Biomarker reported on Friday it has closed on a financing round and appointed a new CEO.

The amount of the funding was not disclosed. In a statement, the company, based in Maastricht, Netherlands, said it will be used to further develop its product pipeline and discover novel biomarkers "that improve diagnosis, prognosis, and management of cardiac diseases."

Funding came from Life Sciences Fund Amsterdam and Limburg Ventures, ACS said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.